A Phase 3 interventional study of HUC3-637 and HUC3-637-R in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension, sponsored by Huons Co., Ltd.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Huons Co., Ltd. (part of Huons Global) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Glaucoma, Open-Angle with a site in Korea, Republic of — 3 open to participants now, 3 under way, 2 of them phase 3. Glaucoma, Open-Angle · Korea, Republic of.
Among the 21 studies in Glaucoma, Open-Angle with a site in Korea, Republic of, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 7 in phase 3, and was the 20th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →3 of the 21 studies in Glaucoma, Open-Angle with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Kukje Pharma · Sites in Korea, Republic of
Ages 19+
Kukje Pharma · Sites in Korea, Republic of
Ages 19+
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 19 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 206 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 150 across the 15 interventional studies, 566 across the 6 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under Huons Co., Ltd., one of the names counted as Huons Global. Under that name alone:
Huons Co., Ltd. is the lead sponsor of 29 studies on the registry; 5 are open to participants now.
Huons Global has 1 study filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
2 of the studies in Glaucoma, Open-Angle with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07662759Phase 3Kukje Pharma[KJ-TFC-005] Phase 3 Study, Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension | 2027-03 |
| NCT07335211Phase 3Huons Co., Ltd.Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Glaucoma, Open-Angle with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dorzolamide, Timolol
Drug: HUC3-637
Dorzolamide, Timolol
Drug: HUC3-637-R
Ophthalmic solution instilled directly into the eye (topical ocular administration)
Ophthalmic solution instilled directly into the eye (topical ocular administration)
Mean change in diurnal IOP
Time frame: 12 week
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Nov 2027, 22 months later.
Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 22 months is below that.
Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.